UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 26, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HOLOGIC, INC. (Exact name of registrant as specified in its c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 26, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 _________________________________________________ ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2020 was $1.347 billion, representing a 70.9% organic growth year-over-year, while non-GAAP earnings per share (EPS) were $2.07, more than tripling compared to the previous year [9][31] - For the full fiscal year 2020, organic revenue growth was 22% and non-GAAP EPS growth was 64% [15][28] - Gross margin increased to 74.2%, up 1,250 basis points, and operating margin rose to 53.7%, an increase of 2,430 basis points [36][37] Business Line Data and Key Metrics Changes - Diagnostics division revenue more than tripled, with molecular sales increasing by 371%, driven by the shipment of approximately 25 million COVID tests, generating $601 million in revenue [32] - Breast Health division reported global sales of $289.2 million, a decrease of 16.2%, but the interventional business remained flat due to the relaunch of the Brevera biopsy system [33] - Surgical division sales were $100.2 million, down 12.9%, but showed improvement compared to previous quarters [34] Market Data and Key Metrics Changes - Domestic sales increased by 52% to $994.9 million, while international sales roughly doubled to $352.1 million, growing 95% organically, particularly in Europe [35] - The company is on track to generate over $1 billion in total European revenue, with committed COVID revenue expected to exceed $600 million [18][19] Company Strategy and Development Direction - The company aims to produce at least 75 million total molecular diagnostic tests per quarter by the end of 2021, significantly increasing capacity from pre-COVID levels [23][22] - Hologic is focusing on expanding its diagnostics platform and pursuing acquisitions to enhance growth, with a strong emphasis on maintaining cash flow discipline [50][51] - The company is also enhancing its market positioning through contributions to the pandemic response, which is expected to benefit other product lines [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for COVID testing, even post-vaccine, highlighting the importance of asymptomatic testing [52][53] - The company anticipates strong financial results for Q1 2021, with revenue guidance between $1.35 billion and $1.425 billion, reflecting continued growth [40][41] - There is an expectation of gradual recovery in non-COVID related business lines, particularly in Breast Health and Surgical divisions [44][45] Other Important Information - The company repurchased approximately 1.7 million shares for about $100 million in Q4 2020, totaling 13 million shares for $654 million for the full year [28][39] - Hologic's cash flow from operations was $442 million in Q4, contributing to a strong balance sheet with $701 million in cash at the end of the quarter [38][39] Q&A Session Summary Question: Focus on M&A and COVID revenues - Management indicated a focus on broadening the diagnostics platform through acquisitions, while remaining within annual cash flow constraints [50][51] Question: Asymptomatic testing implications - Management believes the asymptomatic approval will drive ongoing demand for testing, even post-vaccine, as governments will likely continue monitoring health [52][53] Question: Sustainability of operating margins - Operating margins are expected to remain strong, with guidance for EPS in Q1 2021 indicating continued robust demand [56][57] Question: Capacity expansion challenges - Management discussed the incremental nature of capacity expansion, with some delays expected in the immediate quarters [66][67] Question: Performance in Breast Health - The Breast Health division is expected to gradually improve, with a focus on service and disposable products contributing positively [70][71]

Hologic, Inc. (NASDAQ:HOLX) Q3 2020 Results Conference Call July 29, 2020 4:30 PM ET Company Participants Mike Watts - VP, IR and Corporate Communications Steve MacMillan - Chairman, President and CEO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi. Chris Lin - Cowen Tycho Peterson - JP Morgan Dan Leonard - Wells Fargo Brian Weinstein - William Blair Jack Meehan - Nephron Research Anthony Petrone - Jefferies Dan Brennan - UBS Ivy Ma - Bank of America Richard Newitter - SVB Leerink ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 27, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HOLOGI ...

Reintroducing a Unique Asset in Women's Health May 2020 May 2020 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company's strategies, positioning, resource ...

Hologic, Inc. (NASDAQ:HOLX) Q2 2020 Earnings Conference Call April 29, 2020 4:30 PM ET Company Participants Michael Watts - VP, IR & Corporate Communications Stephen MacMillan - Chairman, CEO & President Karleen Oberton - CFO Conference Call Participants Tycho Peterson - JPMorgan Chase & Co. Patrick Donnelly - Citigroup Brian Weinstein - William Blair & Company Doug Schenkel - Cowen and Company Ivy Ma - Bank of America Merrill Lynch Anthony Petrone - Jefferies David Lewis - Morgan Stanley Daniel Leonard - W ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q HOLOGIC, INC. (Exact name of registrant as specified in its charter) __________________________________________________________ or Massachusetts 01752 Delaware 04-2902449 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 250 Campus Drive, Marlborough, (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2020 was $850.5 million, representing a 2.8% growth year-over-year, slightly above guidance [13][39] - Organic revenue growth was 4.6%, outperforming previous guidance of 1.2% to 3% [13][39] - EPS for the quarter was $0.61, at the high end of guidance despite losses from the divested Cynosure business [14][39] - Gross margins decreased to 61.6%, down 60 basis points year-over-year, primarily due to Cynosure's performance and product mix [41][102] - Operating margin was 27.5%, a decrease of 170 basis points, while net margins increased to 19.3%, up 40 basis points [43] Business Line Data and Key Metrics Changes - Surgical division revenue grew by 10.2%, marking the fastest growth in 11 quarters, driven by MyoSure and new product launches [30][36] - Diagnostics revenue increased by 5.5%, with Molecular sales growing 9% year-over-year [24][25] - Breast Health sales totaled $331.1 million, a 2.4% increase, with growth impacted by a tough prior year comparison [17][18] - GYN Surgical sales reached $119.1 million, driven by core products and new innovations [30] Market Data and Key Metrics Changes - Domestic sales were $632.7 million, up 1.8%, while international sales were $217.8 million, up 6% [15] - International Molecular sales increased by 22.2%, reflecting strong growth in women's health tests and viral load assays [25] - Core U.S. sales have maintained a low double-digit growth rate over the past three years, with expectations to continue this trend [15] Company Strategy and Development Direction - The company aims to focus on women's health, leveraging its strong cash flow for growth-accretive acquisitions and share buybacks [11][35] - The divestiture of Cynosure allows the company to concentrate on its core businesses, enhancing operational focus and forecasting ability [10][60] - The company plans to pursue smaller, division-led acquisitions to enhance its existing commercial channels [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the core businesses, raising guidance for organic revenue growth to 4% to 5% for the year [49] - The company anticipates continued strong performance in Surgical and Molecular Diagnostics, with optimism about international growth opportunities [36][56] - Management acknowledged the challenges posed by the prior year comparisons but remains positive about the growth trajectory [36][108] Other Important Information - The company executed a $205 million accelerated share repurchase program and plans an additional $500 million repurchase program [40] - The leverage ratio stood at 2.5x, with a comfortable range expected between 2.5 and 3x [45] Q&A Session Summary Question: Impact of Cynosure divestiture on focus - Management noted that while the core U.S. businesses were not significantly distracted, senior management was focused on Cynosure, and the divestiture allows for increased focus on core operations [60] Question: Organic revenue growth guidance related to Cynosure - Management indicated that the upward revision in guidance reflects increased confidence in core businesses rather than a significant drag from Cynosure [67] Question: Performance of Molecular business and flu season impact - Management stated that the flu season did not significantly benefit the Panther Fusion respiratory assays, as the business remains small [69] Question: Acceleration of growth by segment - Management highlighted that growth acceleration is primarily seen in the Surgical and Diagnostics segments [73] Question: International market share and growth potential - Management expressed optimism about the long-term growth potential in international markets, indicating significant runway for expansion [87] Question: Margin improvement initiatives - Management emphasized ongoing efforts to improve operating margins through supply chain efficiencies and strategic investments [96]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 28, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HOLOGIC, INC. (Exact name of registrant as specified in its charter) ________________________ ...